Boston Scientific announced a definitive agreement to acquire Cortex Inc., a private medical technology company supported by Ajax Health that specializes in diagnostic mapping solutions for atrial fibrillation.
The acquisition, slated for completion in the first half of 2025, expands Boston Scientific's electrophysiology offerings with Cortex’s OptiMap System, a tool for identifying AF triggers outside of the pulmonary veins, facilitating targeted ablation strategies.
Cortex’s OptiMap System combines a basket catheter with an advanced algorithm to pinpoint active AF sites, supporting a more individualized approach to ablation. It received FDA 510(k) clearance in 2023 and has shown promising results in the FLOW-AF trial, where it improved one-year freedom from AF by 51% compared to traditional methods.
Nick Spadea-Anello, Boston Scientific’s global president of electrophysiology, highlighted the value of Cortex's technology, stating, "The addition of the Cortex technology complements our electrophysiology portfolio with a differentiated cardiac mapping offering to assist with complex AF cases."
While financial details of the acquisition were not disclosed, Boston Scientific expects the transaction to have a minimal impact on adjusted earnings per share in 2025 and to be slightly dilutive on a GAAP basis due to related charges.
